Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

ONVO opened at $0.99 on Friday. Organovo has a fifty-two week low of $0.89 and a fifty-two week high of $2.05. The firm has a market capitalization of $9.92 million, a price-to-earnings ratio of -0.46 and a beta of 0.91. The company’s 50 day moving average price is $1.04 and its two-hundred day moving average price is $1.13.

Organovo (NASDAQ:ONVO) last posted its earnings results on Thursday, February 8th. The medical research company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.08 million. As a group, equities research analysts predict that Organovo will post -1.74 EPS for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.